Cd4+ T Cell Subsets during Virus Infection: Protective Capacity Depends on Effector Cytokine Secretion and on Migratory Capability by Maloy, Kevin J. et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2000/06/2159/12 $5.00
Volume 191, Number 12, June 19, 2000 2159–2170
http://www.jem.org/cgi/current/full/191/12/2159
 
2159
 
CD4
 
1
 
 T Cell Subsets during Virus Infection:
Protective Capacity Depends on Effector Cytokine
Secretion and on Migratory Capability
 
By Kevin J. Maloy,
 
*
 
 Christoph Burkhart,
 
*
 
 
 
Tobias M. Junt,
 
*
 
Bernhard Odermatt,
 
*
 
 Annette Oxenius,
 
*
 
 Luca Piali,
 
‡
 
Rolf M. Zinkernagel,
 
*
 
 and Hans Hengartner
 
*
 
From the 
 
*
 
Department of Pathology, Institute of Experimental Immunology, CH-8091 Zürich, 
 
Switzerland; and the 
 
‡
 
Department of Research, University Children’s Hospital, CH-4031 Basel, 
Switzerland
 
Abstract
 
To analyze the antiviral protective capacities of CD4
 
1
 
 T helper (Th) cell subsets, we used
 
transgenic T cells expressing an I-A
 
b
 
–restricted T cell receptor specific for an epitope of vesicu-
lar stomatitis virus glycoprotein (VSV-G). After polarization into Th1 or Th2 effectors and
adoptive transfer into T cell–deficient recipients, protective capacities were assessed after infec-
tion with different types of viruses expressing the VSV-G. Both Th1 and Th2 CD4
 
1
 
 T cells
could transfer protection against systemic VSV infection, by stimulating the production of neu-
tralizing immunoglobulin G antibodies. However, only Th1 CD4
 
1
 
 T cells were able to medi-
ate protection against infection with recombinant vaccinia virus expressing the VSV-G (Vacc-
IND-G). Similarly, only Th1 CD4
 
1
 
 T cells were able to rapidly eradicate Vacc-IND-G from
peripheral organs, to mediate delayed-type hypersensitivity responses against VSV-G and to
protect against lethal intranasal infection with VSV. Protective capacity correlated with the
ability of Th1 CD4
 
1
 
 T cells to rapidly migrate to peripheral inflammatory sites in vivo and to
respond to inflammatory chemokines that were induced after virus infection of peripheral tis-
sues. Therefore, the antiviral protective capacity of a given CD4
 
1
 
 T cell is governed by the ef-
fector cytokines it produces and by its migratory capability.
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Introduction
 
In the case of cytopathic viruses, T cell–dependent cyto-
 
kines together with neutralizing antibodies are usually essen-
tial for viral eradication and protection against reinfection
(1, 2). CD4
 
1
 
 T cells play a crucial role in many antiviral
immune responses. As well as their direct antiviral effects
 
via the production of cytokines such as IFN-
 
g
 
 and TNF-
 
a
 
(3, 4), they provide the cognate signals that induce the pro-
duction of protective virus-neutralizing IgG by specific B
cells (5) and enhance the magnitude of antiviral CTL re-
sponses (6–8). Several experimental models of viral infec-
tion have emphasized the important role CD4
 
1
 
 T cells may
play in the eradication of viruses by both humoral and cell-
mediated mechanisms. Mice deficient in CD8
 
1
 
 CTLs can
clear influenza A virus, and adoptively transferred CD4
 
1
 
 T
cell clones have been shown to be able to promote recov-
ery from lethal infection (9–11). In addition, CD8
 
1
 
 CTL–
deficient mice can also effectively control vaccinia virus in-
fection (12, 13). Furthermore, poliovirus-specific CD4
 
1
 
 T
cell clones can confer protection against lethal infection by
stimulating neutralizing antibody production (14).
Effector CD4
 
1
 
 T cells can be subdivided, on the basis of
the cytokines that they secrete, into distinct populations
that direct different types of immune response. Two main
subsets of effector CD4
 
1
 
 T cells have been described: Th1
cells produce inflammatory cytokines such as IFN-
 
g
 
 and
TNF and participate in cell-mediated immune responses,
whereas Th2 cells secreting IL-4, IL-5, IL-6, IL-10, and
IL-13 primarily help B cells produce antibodies and also
mediate immunity against intestinal nematodes (15–17).
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CD4 T Cell Subsets in Virus Infection
 
Although the roles of Th1 and Th2 CD4
 
1
 
 T cells in pro-
tection against some parasitic infections such as 
 
Leishmania
 
and 
 
Nippostrongylus
 
 have been well described (18–20), thus
far little is known about the ability of these cells to protect
against different types of virus infection. Vesicular stomati-
tis virus (VSV)
 
1
 
 infection of immunocompetent mice in-
duces a rapid T cell–independent neutralizing IgM re-
sponse, followed by production of neutralizing IgG
antibodies that are strictly dependent on CD4
 
1
 
 T cell help
(5). CD4
 
1
 
 T cells seem to be crucial for recovery from pri-
mary infections and for eliciting neutralizing IgG antibodies
required for protection against reinfection (21, 22). To an-
alyze the antiviral protective capacities of CD4
 
1
 
 Th cell
subsets, we used transgenic mice (designated tg7) express-
ing an MHC class II (I-A
 
b
 
)–restricted TCR specific for a
peptide derived from the glycoprotein of VSV (VSV-G) on
50% of CD4
 
1
 
 T cells (23). Naive tg7 transgenic CD4
 
1
 
 T
cells facilitated protective VSV-neutralizing IgG produc-
tion after adoptive transfer into T cell–deficient recipients,
but were unable to confer cell-mediated antiviral protec-
tion against recombinant vaccinia virus expressing the
VSV-G (23). In contrast, in vitro–primed tg7 CD4
 
1
 
 T cells
rapidly eliminated recombinant vaccinia virus from periph-
eral tissues (23). Here, we analyzed the protective capacities
of distinct Th1 and Th2 effector populations of CD4
 
1
 
 T
cells in different types of antiviral responses, namely, the in-
duction of VSV-neutralizing IgG antibodies and the cell-
mediated clearance of recombinant vaccinia virus express-
ing VSV-G.
 
Materials and Methods
 
Mice.
 
C57BL/6 (H-2
 
b
 
) mice, TCR transgenic tg7 mice (23),
and SMARTA mice (24) were obtained from the breeding colo-
nies of the Institut für Zuchthygiene, Zürich, Switzerland. T
cell–deficient mice (TCR-
 
b
 
2
 
/
 
2
 
d
 
2
 
/
 
2
 
) (25) on a C57BL/6 (H-2
 
b
 
)
background were obtained from The Jackson Laboratory.
 
Cytofluorimetric Analysis of Intracellular Cytokines.
 
The follow-
ing mAbs were used: FITC-conjugated anti–IFN-
 
g
 
, PE-conju-
gated anti–IL-4, FITC-conjugated anti–TNF-
 
a
 
, PE-conjugated
anti–IFN-
 
g
 
, and FITC-conjugated IL-10 (all from BD PharMin-
gen). Staining was performed as described previously (26). In
brief, aliquots of 5 
 
3 
 
10
 
5
 
 CD4
 
1
 
 T cells were stimulated in vitro
at 37
 
8
 
C for 4 h in RPMI 1640/10% FCS containing PMA (10
ng/ml), ionomycin (100 ng/ml), and monensin (2 mM; all from
Sigma-Aldrich). Samples were then stained for 30 min at 4
 
8
 
C
 
with Tricolor–anti-CD4 (Caltag). Surface staining was fixed by
incubation in 100 
 
m
 
l of PBS/4% paraformaldehyde for 10 min,
and the cells were permeabilized by addition of 2 ml permeabili-
zation buffer (PB: PBS/1% saponin/0.05% sodium azide, both
from Sigma-Aldrich) for 10 min. Samples were stained for 30
min at 4
 
8
 
C in PB containing the appropriate anticytokine anti-
bodies. After washing twice with PB, samples were resuspended
in FACS buffer and analyzed using a FACScan™. To control for
nonspecific intracellular staining, parallel samples of stimulated
and permeabilized CD4
 
1
 
 T cells were stained with PE-conju-
gated isotype-matched mAbs of irrelevant specificity, which did
not result in any staining signal.
 
Viruses and Inactivation of VSV.
 
VSV serotype Indiana (VSV-
IND, Mudd-Summers isolate) and VSV serotype New Jersey
(VSV-NJ, Pringle isolate) were grown on BHK 21 cells and
plaqued on Vero cells (27). UV light inactivation of VSV was
performed under a 15 W UV lamp for 4 min and verified by
plaquing on Vero cells (28). Recombinant vaccinia viruses ex-
pressing the VSV-IND glycoprotein (Vacc-IND-G [29]) or lym-
phocytic choriomeningitis virus nucleoprotein (LCMV-NP)
(Vacc-LCMV-NP [30]) were grown and plaqued on BSC 40
cells. LCMV isolate WE (31) was grown on L929 cells. Recom-
binant baculoviruses expressing VSV-IND-G or VSV-IND-NP
were obtained and grown as described previously (32).
 
Immunizations and Assessment of Antiviral Immunity.
 
Mice
were immunized intravenously or intranasally with 2 
 
3
 
 10
 
6
 
 PFU
of live or inactivated VSV-IND or VSV-NJ. Sera were collected
by bleeding from the retroorbital plexus at different time points
after immunization for determination of VSV-specific neutraliz-
ing antibody titers using a plaque assay as described previously
(33). To determine IgG titers, undiluted serum was pretreated
with an equal volume of 0.1 M 2-ME in saline (34).
Alternatively, mice were infected intraperitoneally with 5 
 
3
 
10
 
6
 
 PFU of Vacc-IND-G or Vacc-LCMV-NP. Organs were
harvested at the indicated time points, and the vaccinia titers
were determined on BSC 40 monolayers as described previously
(35).
For footpad delayed-type hypersensitivity (DTH) responses,
mice received 10 
 
m
 
g of baculovirus-derived recombinant VSV-G
(Bac-G) or recombinant VSV-NP (Bac-NP), or 500 PFU
LCMV-WE, in a total of 50 
 
m
 
l into the right hind footpad. Foot-
pad swelling was monitored daily using calipers (Kroeplin).
 
T Cell Proliferative Assays and Cytokine Production.
 
Prolifera-
tive responses and cytokine secretion by tg7 Th1 and Th2 effec-
tor cells were assayed after in vitro restimulation with irradiated
C57BL/6 spleen cells and VSV-G peptide p8 (36; VSV-G amino
acids 415–433), using [
 
3
 
H]thymidine incorporation and ELISA,
respectively, as described previously (23).
 
Polarization of Transgenic CD4
 
1
 
 T Cells into Th1 and Th2
Cells.
 
Effector Th1 and Th2 cells were generated by in vitro
polarization of naive transgenic tg7 CD4
 
1
 
 cells as described pre-
viously (37). Naive tg7 CD4
 
1
 
 spleen cells were obtained at a pu-
rity of 98% by magnetic cell sorting (MACS) with anti-CD4 mi-
crobeads (Miltenyi Biotec). Aliquots of 5 
 
3
 
 10
 
5
 
 CD4
 
1
 
 T cells
were cultured in 24-well tissue culture plates (TPP) in 2 ml
RPMI 1640 medium containing 10% FCS, penicillin, streptomy-
cin, 
 
l
 
-glutamine, and 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME (proliferation medium),
in the presence of 5 
 
3
 
 10
 
6
 
 irradiated C57BL/6 spleen cells plus
p8 (1 
 
m
 
g/ml). Th1 cultures were supplemented with 50 U/ml
recombinant murine IL-2 (rmIL-2; BD PharMingen), whereas
Th2 cultures contained rmIL-2 plus rmIL-4 (500 U/ml; BD
PharMingen) and polyclonal sheep anti–IFN-
 
g
 
 antibodies (1:100
[38]). After 4 d of culture at 37
 
8
 
C in 5% CO
 
2
 
, cells were washed
 
1
 
Abbreviations used in this paper:
 
 Bac-G, baculovirus-derived recombinant
VSV-G; Bac-NP, baculovirus-derived recombinant VSV-NP; CCR, CC
chemokine receptor; CNS, central nervous system; CXCR, CXC
chemokine receptor; DTH, delayed-type hypersensitivity; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; LCMV, lymphocytic chorio-
meningitis virus; MCP, monocyte chemotactic protein; MDC, mac-
rophage-derived chemokine; Mig, monokine induced by IFN-
 
g
 
; MIP,
macrophage inflammatory protein; RANTES, regulated upon activation,
normal T cell expressed and secreted protein; RT, reverse transcription;
SDF, stromal cell–derived factor; VSV, vesicular stomatitis virus; VSV-
IND, VSV serotype Indiana; Vacc-IND-G, recombinant vaccinia virus
expressing VSV-IND glycoprotein; VSV-NJ, VSV serotype New Jersey;
UV
 
i
 
-VSV, UV-inactivated VSV. 
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and expanded for a further 4–5 d in 6-well tissue culture plates
(TPP) with 5 ml proliferation medium containing rmIL-2 (Th1
cultures) or rmIL-2 plus rmIL-4 (Th2 cultures). To obtain irre-
versibly polarized effector populations, three identical rounds of
the above in vitro stimulation were performed (39). Effector cells
were washed twice in HBSS before use.
 
Adoptive Transfer of Antiviral Immunity.
 
TCR-
 
b
 
2
 
/
 
2
 
d
 
2
 
/
 
2
 
 or
C57BL/6 mice were adoptively transfused intravenously with the
indicated numbers of transgenic Th1 or Th2 CD4
 
1
 
 T cells and
challenged 24 h later with virus or recombinant viral proteins as
described in the figure legends.
 
Immunohistochemistry.
 
Immunohistochemical analysis was
performed as described previously (40). In brief, organs were im-
mersed in HBSS, snap frozen in liquid N
 
2
 
, and 5-
 
m
 
m-thick cry-
ostat sections were cut and fixed in acetone. Sections were
stained with rat antibodies against CD4 or CD8, followed by al-
kaline phosphatase–labeled goat anti–rat Ig (TAGO) and then al-
kaline phosphatase–labeled donkey anti–goat Ig (Jackson Immu-
noResearch Laboratories). Alkaline phosphatase was detected
with naphthol A-BI phosphate and New Fuchsin (Fluka), result-
ing in a red color reaction. Sections were counterstained with
Mayer’s hemalum.
 
Analysis of Chemokine and Chemokine Receptor Expression by Re-
verse Transcription PCR.
 
RNA was extracted with 10 
 
m
 
g carrier
yeast tRNA using the TRIZOL reagent (GIBCO BRL). 1 
 
m
 
g
RNA extracted from ovaries isolated from C57BL/6 mice 48 h
after infection with 2 
 
3 
 
10
 
6
 
 PFU Vacc-IND-G was used in the
reverse transcription (RT) reaction. Alternatively, RNA ex-
tracted from 2 
 
3 
 
10
 
6
 
 polarized Th1 or Th2 cells was digested
with DNase (Roche) in 20 mM Tris-HCl (pH 8.0) containing
100 mM MgCl
 
2
 
. RT was carried out using Superscript II reverse
transcriptase and random hexamer primers (GIBCO BRL). Con-
ventional PCR was performed in 50-
 
m
 
l volumes using the follow-
ing primer pairs: JE (monocyte chemotactic protein [MCP]-1),
5
 
9
 
-CCCACTCACCTGCTGCTACT-3
 
9
 
 and 5
 
9
 
-GTCTG-
GACCCATTCCTTCTT-3
 
9
 
; macrophage-derived chemokine
(MDC), 5
 
9
 
-GCCAGGACTACATCCGTCAC-3
 
9
 
 and 5
 
9
 
-GAA-
GAATAGGGCTTGCTGAG-3
 
9
 
; macrophage inflammatory
protein (MIP)-1a, 59-ACTGCCCTTGCTGTTCTTCT-39 and
59-CCCAGGTCTCTTTGGAGTCA-39; MIP-1b, 59-CTCT-
GCGTGTCTGCCCTC-39; regulated on activation normal T
cell expressed and secreted protein (RANTES), 59-CGAAG-
GAACCGCCAAGTGTG-39; monokine induced by IFN-g
(Mig), 59-TCTTTTCCTTTTGGGCATCA-39 and 59-GAC-
GACGACTTTGGGGTGTT-39; IP-10, 59-GTGCTGCCGT-
CATTTTCTGC-39 and 59-AGGCTCTCTGCTGTCCATCA-
39; stromal cell–derived factor (SDF)-1a, 59-TAAAGACACTC-
CGCCATAGC-39 and 59-ACTCAGGACAAGGCATCTGT-39;
CC chemokine receptor (CCR)2, 59-TCAGTTCATCCACGG-
CATAC-39 and 59-GAGCAGGAAGAGCAGGTCAG-39; CCR4,
59-CAGGTCTACTCGGCTGACAT-39 and 59-TCCACTCAA-
GGGCTCATTGT-39; CCR5, 59-GAGTGGGTCTTTGGGAA-
CAT-39; CXC chemokine receptor (CXCR)3, 59-TATGC-
CTTTGTGGGAGTGAA-39 and 59-AGGGATGGCTGAG-
TTCTACT-39; and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), 59-CATCAAGAAGGTGGTGAAGC-39 and 59-CCT-
GTTGCTGTAGCCGTATT-39. PCR conditions were: 948C
for 30 s, 558C for 45 s, and 728C for 30 s, repeated for 35 cycles.
cDNA templates for the GAPDH reference PCR were diluted in
10-fold steps to avoid PCR signal saturation. After electrophoresis
in an ethidium bromide–stained 1.5% agarose gel, the lumines-
cence of nonsaturated amplicons was densitometrically quantitated
using the Image Station 440 CF and the 1D software (Kodak
Digital Science, Eastman Kodak Co.). Band fluorescence intensi-
ties were expressed in arbitrary units, calculated as a ratio of the
reference GAPDH signal.
Chemokine Migration Assays. Migration of polarized Th1 and
Th2 cells was assayed with Transwell filters (3-mm high density
pores; Becton Dickinson) using 5 3 106 cells/well in RPMI
1640/2% FCS in the upper chamber with chemokine placed in
the lower chamber. After 1 h at 378C, the upper chamber was re-
moved and the cells in the lower chamber were quantified with
FACS® by counting the total number of cells per minute. Results
were expressed in migration indices: [(cells migrating in response
to test chemokine/cells migrating spontaneously) 2 1] 3 100.
Spontaneous migration was assessed without chemokine in the
lower chamber.
Results
Characterization of Polarized Transgenic Th1 and Th2
Cells. Transgenic (tg7) CD41 T cells expressing a TCR
that recognizes a peptide (p8) derived from the VSV-G in
association with I-Ab (23) were polarized by three rounds
of in vitro stimulation with p8-bearing APCs (37). Polar-
ized Th1 effector cells secreted high amounts of IFN-g and
no IL-4, whereas Th2 effectors produced high levels of IL-4
and no IFN-g (Fig. 1 A). Intracellular cytokine staining
showed that some heterogeneity existed within these effec-
tor populations in that Th1 effectors contained cells pro-
ducing TNF-a and/or IFN-g, whereas Th2 effectors con-
tained cells producing IL-4 and/or IL-10 (Fig. 1 B). Th1
and Th2 effector cells mounted similar proliferative re-
sponses when cultured with p8 in vitro (Fig. 1 C).
Both Th1 and Th2 Cells Provide Help for VSV-neutralizing
Protective IgG Responses. Although T cell–deficient TCR-
b2/2d2/2 mice mount normal T cell–independent neutral-
izing IgM responses to VSV, they do not produce CD41 T
cell–dependent neutralizing IgG antibodies (5, 41). Indeed,
despite producing neutralizing IgM antibodies, VSV-infected
TCR-b2/2d2/2 mice succumbed to infection on around
day 14 after infection (Fig. 2 A), confirming previous find-
ings with nude mice (22). In contrast, TCR-b2/2d2/2
mice adoptively transfused with 106 VSV-specific Th1 or
Th2 CD41 T cells produced high titers of VSV-neutral-
izing IgG and were completely protected against disease
(Fig. 2).
To evaluate the sensitivity of Th1 and Th2 cells to facili-
tate neutralizing antibody responses, graded numbers of
VSV-specific Th1 or Th2 cells were adoptively transferred
into naive C57BL/6 mice and the recipients were subse-
quently challenged with UV-inactivated VSV (UVi-VSV).
Nonreplicating UVi-VSV efficiently triggers T cell–inde-
pendent IgM responses, but does not induce isotype
switching to IgG unless excess VSV-specific Th cells are
present (23, 28). C57BL/6 mice adoptively transferred
with Th1 or Th2 CD41 T cells produced high titers of
VSV-neutralizing IgG after challenge with UVi-VSV, and
in both cases at least 105 effector CD41 T cells were re-
quired to support isotype switching (Fig. 3 A). Th1 cells
induced the production of IgG2a and IgG2b, whereas Th2
cells promoted IgG1 and IgG2b secretion (Fig. 3 B).2162 CD4 T Cell Subsets in Virus Infection
Th1 CD41 T Cells, but Not Th2 CD41 T Cells, Can
Adoptively Transfer Cell-mediated Protection against Recombi-
nant Vaccinia Virus. Previous work has shown that
C57BL/6 mice primed with VSV-IND were resistant
against challenge with a recombinant vaccinia virus express-
ing the VSV-IND glycoprotein (Vacc-IND-G) and that
this protection was mediated by CD41 T cells (42). There-
fore, we examined whether the antivaccinia protection
conferred by VSV-G–specific CD41 T cells was dependent
on their effector phenotype. T cell–deficient TCR-b2/2
d2/2 mice were unable to control infection with Vacc-
IND-G, developing a progressive wasting disease that cul-
minated in death z3–4 wk after infection (Fig. 4 A). Adop-
tive transfer of 107 Th1 tg7 CD41 T cells completely pro-
tected the TCR-b2/2d2/2 mice, whereas transfer of 107
Th2 tg7 CD41 T cells failed to protect TCR-b2/2d2/2
mice against Vacc-IND-G (Fig. 4 A). Death correlated with
the presence of vaccinia virus in peripheral organs in mice
that had received Th2 tg7 CD41 T cells, whereas those re-
Figure 1. Characterization of polarized Th1 and Th2 effector cells.
Polarized Th1 and Th2 tg7 CD41 effectors were restimulated in vitro
with irradiated splenic APCs plus p8 for 72 h. Secretion of IL-4 and
IFN-g was assayed by ELISA (A) and proliferation of the cells was mea-
sured using [3H]thymidine incorporation (C). Intracellular cytokine
staining of Th1 and Th2 effectors was performed after in vitro restimula-
tion with PMA and ionomycin (B). Results shown are representative of
three similar experiments.
Figure 2. Both Th1 and Th2
cells can protect T cell–deficient
mice against VSV infection, by
inducing the production of neu-
tralizing IgG antibodies. Groups
of 6 TCR-b2/2d2/2 mice were
adoptively transfused with 107
Th1 or Th2 tg7 CD41 T cells,
and 24 h later recipients were in-
fected with 2 3 106 PFU of live
VSV-IND intravenously. (A)
Mice were monitored daily for
hind limb paralysis and killed
when seriously ill. (B) On indi-
cated days, blood was taken and
the serum was analyzed for the
presence of VSV-IND–neutral-
izing IgM and IgG. Mean titers
from groups of five to six mice
are shown, and intragroup varia-
tions were #2 titer steps. One
of two similar experiments is
shown.
Figure 3. Adoptively trans-
ferred Th1 and Th2 cells mediate
quantitatively similar, but quali-
tatively different, Ig class switch-
ing in vivo. Graded numbers of
Th1 or Th2 tg7 CD41 T cells
were adoptively transferred intra-
venously into syngeneic TCR-
b2/2d2/2 mice, and recipients
were immunized 24 h later with
2 3 106 PFU UVi-VSV intrave-
nously. (A) On indicated days,
blood was taken and the serum
was analyzed for the presence of
VSV-IND–neutralizing IgM and
IgG. Mean titers from groups of
two to three mice are shown,
and intragroup variations were
#2 titer steps. (B) VSV-specific
IgG isotypes present in sera iso-
lated on day 20 after immuniza-
tion from mice receiving 107
Th1 or Th2 cells were assayed by
ELISA. Symbols represent indi-
vidual sera. One of two similar
experiments is shown.2163 Maloy et al.
ceiving Th1 tg7 CD41 T cells remained healthy and had no
detectable vaccinia virus (Fig. 4 B). The inability of Th2
cells to protect against lethal vaccinia virus infection was not
due to inefficient inactivation of these cells, since the TCR-
b2/2d2/2 mice that received Th2 cells mounted strong
VSV-G–specific neutralizing antibody responses (Fig. 4 C).
However, as vaccinia virus may spread from cell to cell by
using actin filaments to form enveloped particles which are
resistant to antibody (43, 44) and because the VSV-G is not
expressed on the surface of the Vacc-IND-G (29), neutral-
izing antibodies are unable to clear the infection.
Protection against Vaccinia Correlates with Enhanced Migra-
tion of Th1 CD41 T Cells to Peripheral Tissues. In a second
approach, we examined the ability of Th1 and Th2 cells to
rapidly eradicate Vacc-IND-G from peripheral solid or-
gans. Thus, normal C57BL/6 mice were adoptively trans-
fused with VSV-G–specific CD41 T cells and challenged
with Vacc-IND-G. In naive female C57BL/6 mice, the
Vacc-IND-G grew well in ovaries, with titers detectable
on day 2 and peaking around day 5 (Fig. 5 A). Adoptive
transfer of 107 naive tg7 CD41 or Th2 tg7 CD41 T cells
had no influence on the vaccinia virus titers in ovaries,
whereas mice receiving $106 Th1 tg7 CD41 T cells rap-
idly eradicated the virus (Fig. 5 A). Histological analysis of
ovaries showed that the transferred Th1 cells were present
in the ovaries on day 2 after infection (Fig. 5 C), whereas
naive or Th2 tg7 CD41 T cells did not migrate into the
ovaries at this time point (Fig. 5, B and D). By day 5 after
infection, extensive inflammatory infiltrates were present in
Figure 4. Th1, but not Th2,
cells can protect T cell–deficient
mice from vaccinia virus infec-
tion. Groups of 6 TCR-b2/2d2/2
mice were adoptively trans-
fused with 107 Th1 or Th2 tg7
CD41 T cells, and 24 h later re-
cipients were infected with 107
PFU of Vacc-IND-G intraperi-
toneally. (A) Mice were moni-
tored daily for signs of disease
and were killed when seriously
ill. (B) Vacc-IND-G titers in or-
gans from sick (Control or Th2
recipients) or healthy (Th1 re-
cipients) mice were determined
by plaquing. Representative re-
sults from three mice per group
are shown, and symbols repre-
sent individual mice. (C) Sera
from the mice shown in A were
analyzed for the presence of
VSV-IND–neutralizing IgM
(day 4 after infection, white bars)
and IgG (day 20 after infection,
striped bars). Mean titers from
groups of five to six mice are
shown, and intragroup variations
were #2 titer steps. One of two
similar experiments is shown.
Figure 5. Th1, but not Th2, cells can protect against peripheral vaccinia virus infection, and this correlates with enhanced migration of Th1 cells to
peripheral organs. (A) Graded numbers of naive or Th1 or Th2 tg7 CD41 T cells were adoptively transferred intravenously into syngeneic naive C57BL/6
female mice. 1 d later, recipients were challenged with 5 3 106 PFU Vacc-IND-G intraperitoneally. After 5 d, ovaries were removed and Vacc-IND-G
titers were determined. Symbols represent individual mice, and one representative experiment of three is shown. (B–J) Immunohistological analysis of
T cell infiltration into the ovary. C57BL/6 mice that had received 107 naive (B, E, and H), Th1 (C, F, and I), or Th2 (D, G, and H) tg7 CD41 T cells
were killed 2 d (B–D) or 5 d (E–J) after Vacc-IND-G challenge, and frozen sections of ovaries were analyzed for infiltration by CD41 (B–G) or CD81
(H–J) T cells using immunohistochemistry. Positively stained cells exhibit a bright red color. Original magnifications: 3125.2164 CD4 T Cell Subsets in Virus Infection
ovaries of mice receiving naive or Th2 tg7 CD41 T cells,
comprising both CD4 and CD8 T cells (Fig. 5, E–J). In
contrast, much smaller infiltrates were present in ovaries of
mice that received Th1 tg7 CD41 T cells (Fig. 5, F and I).
Thus, earlier migration of Th1 cells into peripheral organs
correlated with a rapid elimination of vaccinia virus and a
decreased late inflammatory reaction.
Induction of Virus-specific DTH Responses Confirms That
Th1 Cells, but Not Th2 Cells, Effectively Respond to Peripheral
Antigen Challenge. We next examined Th1 and Th2 cells
for their ability to mediate virus-specific DTH responses.
Thus, normal C57BL/6 mice were adoptively transfused
with VSV-G–specific CD41 T cells and challenged in the
hind footpad with recombinant baculovirus–derived VSV-G
(Bac-G). As shown in Fig. 6 A, control C57BL/6 mice ex-
hibited a small transient increase in footpad thickness, peak-
ing 24 h after injection and declining 48–72 h after injec-
tion. C57BL/6 mice adoptively transfused with Th2 tg7
CD41 T cells had identical responses to control mice (Fig.
6 A). In contrast, mice given Th1 tg7 CD41 T cells
mounted strong DTH responses after challenge with Bac-G,
which peaked 72–96 h after injection and slowly de-
clined thereafter (Fig. 6 A). These responses were antigen
specific, since they were not provoked by challenge with
baculovirus-derived VSV-NP (Bac-NP) (Fig. 6 A). Histo-
logical analysis of footpads showed that the ability of Th1
cells to mediate DTH responses correlated with enhanced
migration and accumulation of CD41 T cells in the foot-
pad, which was evident as early as 48 h after injection (Fig.
6, B–E).
Figure 6. Th1, but not Th2, cells rapidly migrate to inflammatory sites
and mediate DTH responses after peripheral antigen challenge. (A) 107
Th1 or Th2 tg7 CD41 T cells were adoptively transfused intravenously
into syngeneic naive C57BL/6 mice. 1 d later, recipients were challenged
in the right hind footpad with 10 mg Bac-VSV-G or Bac-VSV-NP. Foot-
pad swelling was monitored daily using calipers. Symbols represent mean
values from groups of four to six mice, and intragroup variations were
#0.4 mm. One representative experiment of three is shown. (B–E) Im-
munohistological analysis of CD41 T cell infiltration into the footpad.
Two mice from each group described in A were killed 2 d after antigen
challenge, and frozen sections of footpads were analyzed for infiltration by
CD41 T cells using immunohistochemistry. Positively stained cells ex-
hibit a bright red color. Original magnifications: 350.
Figure 7. Th1, but not Th2, cells rapidly migrate to inflammatory sites
and mediate DTH responses after peripheral challenge with live virus. (A)
107 Th1 or Th2 SMARTA CD41 T cells were adoptively transferred in-
travenously into syngeneic naive C57BL/6 mice. 1 d later, recipients
were challenged in the right hind footpad with 500 PFU LCMV-WE.
Footpad swelling was monitored daily using calipers. Symbols represent
mean values from groups of four to six mice, and intragroup variations
were #0.4 mm. One representative experiment of three is shown. (B–D)
Immunohistological analysis of CD41 T cell infiltration into the footpad.
Two mice from each group described in A were killed 3 d after LCMV-
WE challenge, and frozen sections of footpads were analyzed for infiltra-
tion by CD41 T cells using immunohistochemistry. Positively stained
cells exhibit a bright red color. Original magnifications: 350.2165 Maloy et al.
To examine whether enhanced responsiveness to periph-
eral antigen challenge was a general property of Th1 CD41
T cells, we used SMARTA transgenic CD41 T cells,
which recognize a peptide from LCMV-GP in the context
of I-Ab (24). While control C57BL/6 mice or those that
received Th2 SMARTA CD41 T cells showed no increase
in footpad swelling after infection with LCMV-WE, mice
that received Th1 SMARTA CD41 T cells mounted a
DTH response 72–96 h after infection (Fig. 7 A). This
again correlated with greatly enhanced migration of Th1
CD41 T cells into the footpad (Fig. 7, B–D).
Th1 Cells Exhibit Enhanced Migratory Capacity toward
Chemokines That Are Induced after Virus Infection. Lym-
phocyte migration involves a complex series of adhesive
interactions between T cells and endothelium (45, 46).
Both Th1 and Th2 cells had a phenotype characteristic of
activated T cells, expressing low levels of CD62L and high
levels of CD25, CD69, intracellular adhesion molecule 1
(ICAM-1), and CD49d (very late antigen 4 [VLA-4]), but
there were no readily detectable differences in surface phe-
notype (Maloy, K., unpublished observations). As evidence
is increasing that Th1 and Th2 cells show differential ex-
pression of chemokine receptors (47–49), we examined
whether chemokines may play a role in the preferential mi-
gration of Th1 cells into virus-infected tissues. Using semi-
quantitative RT-PCR analysis, we found that Th1 cells ex-
pressed higher levels of CCR2, CCR5, and CXCR3 than
Th2 cells, whereas CCR4 was expressed at higher levels by
Th2 cells (Fig. 8 A). We then assayed the expression of in-
flammatory chemokines in the ovaries of normal C57BL/6
mice 48 h after intraperitoneal injection of Vacc-IND-G.
As shown in Fig. 8 B, several chemokines were upregu-
lated in the ovaries of vaccinia-infected mice, including
MIP-1a, MIP-1b, RANTES, MDC, and SDF-1a. Most
striking, however, were our observations that the chemo-
kines JE (MCP-1), Mig, and IP-10, which were undetect-
able in uninfected ovaries, were strongly induced after vac-
cinia infection (Fig. 8 B). Using in vitro migration assays,
we found that Th1 cells showed strong migratory responses
to these newly induced chemokines JE, Mig, and IP-10, as
well as to the CCR5-binding chemokine MIP-1b,
whereas Th2 cells migrated either poorly (JE) or not at all
(Mig, IP-10, and MIP-1b) (Fig. 8 C). These results suggest
that virus infection of peripheral tissues leads to the pro-
duction of inflammatory chemokines that preferentially at-
tract Th1 cells.
Th1 Cells, but Not Th2 Cells, Can Protect against Intranasal
Challenge with VSV. Although neutralizing antibodies are
sufficient in mediating protection against VSV administered
systemically, intranasal infection with VSV facilitates rapid
infection of the central nervous system (CNS) via the olfac-
tory nerve, which can be rapidly lethal even in immuno-
competent mice (50, 51). Thus, C57BL/6 mice were
adoptively transfused with Th1 or Th2 tg7 CD41 T cells
24 h before intranasal challenge with 2 3 106 PFU VSV.
As shown in Table I, mice that received Th1 cells were
completely protected against intranasal infection with
VSV-IND, whereas those that received Th2 cells suc-
cumbed to infection with similar kinetics to control
C57BL/6 mice. Protection was again antigen specific, since
Th1 SMARTA CD41 T cells were unable to provide pro-
tection against intranasal infection with VSV-IND and tg7
CD41 T cells were unable to protect against VSV-NJ chal-
lenge (Table I). Protection by Th1 cells correlated with
complete eradication of VSV from the brain, whereas
brains from control mice or those that received Th2 cells
harbored high titers of VSV (Table I).
Virus Infection Preferentially Induces Differentiation of Th1
Cells In Vivo. To examine whether virus infection prefer-
entially induces the development of Th1 effector cells, na-
ive tg7 CD41 T cells were adoptively transferred into
TCR-b2/2d2/2 mice that were subsequently challenged
with VSV or Vacc-IND-G. In the absence of viral chal-
lenge, the adoptively transferred CD41 T cells remained
largely undifferentiated as judged by the low numbers pro-
ducing IFN-g after restimulation (Table II). In contrast, in-
Figure 8. Th1 cells exhibit en-
hanced migratory responses toward
chemokines that are induced after
virus infection. (A) Chemokine re-
ceptor expression by Th1 or Th2
tg7 CD41 T cells. RNA extracted
from 2 3 106 Th1 or Th2 cells was
analyzed using RT-PCR. Signal in-
tensity was calculated as a ratio of
the reference GAPDH signal as de-
tailed in Materials and Methods. (B)
Inflammatory chemokine expres-
sion in virus-infected ovaries. RNA
was extracted from ovaries of
C57BL/6 mice isolated 48 h after
intraperitoneal injection of 2 3 106
PFU Vacc-IND-G, and chemokine
expression was analyzed using RT-
PCR. The receptors for the various
chemokines are also indicated. (C)
Migration of Th1 and Th2 tg7 CD41 T cells in response to chemokines. Migration assays
were performed using an in vitro transwell system.2166 CD4 T Cell Subsets in Virus Infection
fection with VSV-IND, or with Vacc-IND-G, led to the
differentiation of high numbers of IFN-g–secreting CD41
T cells, whereas very few IL-4–producing cells could be
detected (Table II).
Discussion
Our results show that several factors contribute to
whether a given type of CD41 effector T cell can effi-
ciently mediate antiviral protection, including viral at-
tributes such as route of infection and protective mecha-
nisms, as well as T cell characteristics such as cytokine
production and migratory patterns. Furthermore, our find-
ings clearly demonstrate that Th1 CD41 effector T cells
possess much greater antiviral protective capacity than their
Th2 counterparts. Th1 cells were able to mediate protec-
tion against viruses controlled by antibodies (VSV) or cy-
tokines (vaccinia), regardless of the route of virus adminis-
tration. In contrast, although Th2 cells protected against
systemic infection with VSV by inducing neutralizing anti-
bodies, they were unable to eradicate vaccinia virus and
were also unable to efficiently respond to peripheral virus
challenge in several different infection models.
Th1 and Th2 cells showed similar capabilities in helping
B cells produce protective, VSV-neutralizing IgG antibod-
ies, with Th1 cells inducing higher amounts of IgG2a and
Th2 cells inducing IgG1 production. Previous studies with
VSV have shown that antibody concentration, rather than
IgG isotype, is the primary factor in determining protection
(52). There were no quantitative differences in the levels of
neutralizing antibodies induced by Th1 or Th2 cells, or in
the number of effector T cells required to mediate class
switching. It is not surprising that Th1 cells are as capable as
Th2 cells in this respect, since the antibody response against
most viruses is dominated by IgG2a, an isotype that is asso-
ciated with IFN-g production and Th1 responses (53, 54).
The successful control of vaccinia infection depends on
the production of T cell–derived cytokines, most notably
IFN-g and TNF (2). We found that adoptively transferred
Th1, but not Th2, CD41 T cell effectors could protect T
cell–deficient mice from lethal Vacc-IND-G infection,
confirming the important role of Th1-type cytokines in the
eradication of vaccinia virus. This difference did not appear
to be due to less efficient activation of the adoptively trans-
ferred Th2 cells, since the mice that received Th2 cells pro-
duced even higher titers of VSV-G–neutralizing IgG anti-
bodies than those receiving Th1 cells. The preferential
ability of Th1 cells to mediate antivaccinia protection was
confirmed by our experiments examining the clearance of
Vacc-IND-G from peripheral tissues of normal mice. We
previously found that although naive tg7 CD41 T cells
were unable to adoptively transfer protection against pe-
ripheral Vacc-IND-G challenge, in vitro–primed tg7 CD41
T cells quickly eradicated the vaccinia from ovaries (23).
Here, we have extended these findings by showing that
only Th1 CD41 T cells are capable of such antiviral protec-
tion and that rapid clearance of vaccinia correlated with en-
hanced migration of the Th1 cells into ovaries as early as 48 h
after infection. In contrast, Th2 CD41 effector T cells
were unable to clear vaccinia from peripheral tissues and did
not efficiently migrate into infected organs. The ability of
Th1 cells to efficiently respond to peripheral antigen chal-
lenge was confirmed by their induction of footpad DTH
responses in response to either nonreplicating virus antigen
(tg7 Th1 cells to Bac-VSV-G) or live virus (SMARTA Th1
cells to LCMV). Histological analysis showed that the en-
hanced responsiveness of Th1 cells again correlated with
their rapid migration into peripheral tissues. The observed
differences in homing did not appear to be due to preferen-
tial survival or expansion of the Th1 cells in vivo, since we
observed that similar numbers of Th1 and Th2 cells homed
Table I. Protection against Lethal Intranasal VSV Infection by 
Antigen-specific Th1 Cells
Adoptive transfer
Challenge
(2 3 106 PFU)
No. of mice
surviving
VSV titer
in brain
log10 PFU
None  VSV-IND 0/6 6.3 6 1.3
107 tg7 Th1 VSV-IND 6/6 ,1.2
107 tg7 Th2 VSV-IND 0/6 5.8 6 1.8
107 SMARTA Th1 VSV-IND 0/6 5.6 6 1.5
None VSV-NJ 0/6 4.9 6 0.8
107 tg7 Th1 VSV-NJ 0/6 4.5 6 1.2
Naive C57BL/6 mice were adoptively transferred intravenously with
transgenic Th1 or Th2 CD41 T cells. 1 d later, recipients were
challenged with 2 3 106 PFU VSV intranasally. Mice were monitored
daily for hind limb paralysis and killed when seriously ill. Brains were
isolated from killed mice or from surviving mice (on day 21 after
challenge), and VSV titers were measured by plaquing on Vero cells.
Mean VSV titers are shown. One of two similar experiments is shown.
Table II. Virus-induced Differentiation of Th1 Cells In Vivo
Percentage of 
CD41 T cells producing:
Challenge IFN-g TNF-a IL-4
None 16 21 1
UVi-VSV 35 52 8
VSV 51 71 4
Vacc-IND-G 56 76 0
TCR-b2/2d2/2 mice were adoptively transferred with 5 3 106 naive
tg7 CD41 T cells, and 24 h later recipients were injected intravenously
with 2 3 106 PFU of live or UV-inactivated VSV-IND or with 2 3 106
PFU Vacc-IND-G. 1 wk after challenge, spleen cells were isolated, and
the production of cytokines by CD41 T cells was assessed using
intracellular cytokine staining after in vitro stimulation with PMA and
ionomycin. Mean values from groups of three mice from one of two
similar experiments are shown.2167 Maloy et al.
to the spleen and peripheral lymph nodes after adoptive
transfer (Maloy, K., unpublished observations).
Lymphocyte migration into peripheral tissues is a multi-
step process, involving adhesion and extravasation via se-
lectins and integrins and chemotactic attraction by
chemokines (45, 46). The recirculation patterns of T cells
are dependent on their differentiation state; naive T cells
are restricted to the lymphoid tissues, whereas primed T
cells may patrol through peripheral tissues (55, 56). Selec-
tive recruitment of Th1 cells to sites of peripheral inflam-
mation has previously been observed using protein anti-
gens and involves interactions with P- and E-selectin
molecules expressed on vascular endothelium (57). Fur-
thermore, evidence is growing that effector CD41 T cell
subsets differ in terms of chemokine receptor expression,
which may also influence their migratory patterns (47–
49).We found similar differences in chemokine receptor
expression, with Th1 effectors expressing higher levels of
CCR2, CCR5, and CXCR3, whereas Th2 cells had
higher levels of CCR4. Importantly, we found that several
inflammatory chemokines were upregulated in virus-infected
tissues, including MIP-1a, MIP-1b, and RANTES (all
of which bind CCR5) as well as MDC (a CCR4 ligand).
Most significantly, we observed that the chemokines JE
(MCP-1), Mig, and IP-10 were newly induced after vac-
cinia virus infection and these chemokines all bind to re-
ceptors which were expressed at higher levels by Th1 cells
(CCR2 and CXCR3). An almost identical pattern of
chemokine upregulation and induction was observed af-
ter LCMV infection of the footpad (Junt, T.M., unpub-
lished observations) or brain (58). In vitro migration assays
showed that Th1 cells migrated well in response to these
newly induced chemokines, as well as to the upregulated
CCR5 ligand MIP-1b, whereas Th2 cells did not. Taken
together, our results suggest that virus infection induces the
production of chemokines that preferentially attract Th1
cells. Furthermore, they demonstrate positive correlations
among protection against peripheral virus infections, mi-
gration into virus-infected tissues in vivo, and migration in
response to chemokines that are induced after virus infec-
tion, all properties exhibited by Th1 effectors but not by
Th2 cells. Interestingly, the antiviral capacities of effector
CD81 T cells may similarly correlate with their migratory
properties. Effector CD81 T cells can mediate protection
against peripheral vaccinia infection, and this is dependent
on recent antigenic stimulation, which enhances extravasa-
tion of effector T cells (59, 60). In addition, recent studies
with hemagglutinin-specific CD81 effector T cells found
that Tc1 effectors (analogous to Th1 cells) were much
more effective than Tc2 effectors (analogous to Th2 cells)
in protecting against pulmonary infection with influenza
virus, despite the fact that both populations were equally
cytolytic (61). The greater protective capacity of Tc1 ef-
fectors correlated with more rapid migration of these
cells into the airway epithelium and with differences in
chemokine receptor expression between the Tc1 and Tc2
cells (61). Together with our findings, these results demon-
strate that the antiviral protective capabilities of both
CD41 T cells and CD81 T cells are governed not only by
the effector molecules they produce, but also by their mi-
gratory characteristics.
Intranasal inoculation of VSV leads to infection of local
olfactory receptor neurons, which is quickly followed by
acute infection of the CNS (50). Recovery from CNS in-
fection is T cell dependent and is associated with increased
T cell infiltration of the CNS and with enhanced produc-
tion of cytokines that are characteristically present during
Th1 responses (51, 62). We observed that Th1 cells, but
not Th2 cells, were able to protect mice against the lethal
consequences of intranasal challenge with VSV. This again
is likely to have been due to enhanced migration of the
Th1 cells and/or increased production of cytokines such as
IFN-g, which may play a crucial role during viral infection
of the CNS (63).
The primary role of Th1 responses in antiviral protection
was confirmed by our finding that virus infection predomi-
nantly promoted differentiation of Th1 effectors from naive
CD41 T cells in vivo. Our results are consistent with other
reports showing that CD41 T cells with a Th1 cytokine
phenotype contribute to protection against a variety of viral
infections, including influenza virus (10, 11), poliovirus
(14), murine cytomegalovirus (64), herpes simplex virus
(65), and measles virus (66). Viral infection is known to
stimulate the production of IL-12, which has beneficial ef-
fects on many viral infections and is a potent inducer of
Th1 responses (62, 67–69), although it is worth noting that
viruses can induce Th1 responses in the absence of IL-12
(70). Thus, adjuvants that promote Th1 responses may be
the best for vaccinating against cytopathic viruses, which
are controlled by neutralizing antibodies and T cell cyto-
kines (1). However, in the case of noncytopathic viruses,
CD81 CTLs play a central role in protection (71); thus,
caution must be used, since pathological consequences of
excessive virus-specific CD41 T cell activation have been
observed (72).
We thank Lenka Vlk for assistance with the immunohistology and
Norbert Wey for the photographs. This manuscript is dedicated to
the memory of Mary McDermid.
This work was supported by grants from the Swiss National Sci-
ence Foundation and the Kanton Zürich. C. Burkhart was a fellow
of the Studienstiftung des Deutschen Volkes, Bonn, Germany.
Submitted: 3 January 2000
Revised: 19 April 2000
Accepted: 28 April 2000
References
1. Zinkernagel, R.M. 1996. Immunology taught by viruses. Sci-
ence. 271:173–178.
2. Ramshaw, I.A., A.J. Ramsay, G. Karupiah, M.S. Rolph, S.
Mahalingam, and J.C. Ruby. 1997. Cytokines and immunity
to viral infections. Immunol. Rev. 159:119–135.
3. Czarniecki, C.W., C.W. Fennie, D.B. Powers, and D.A. Es-
tell. 1984. Synergistic antiviral and antiproliferative activities
of Escherichia coli-derived human alpha, beta and gamma in-
terferons. J. Virol. 49:490–496.2168 CD4 T Cell Subsets in Virus Infection
4. Wong, G.H.W., and D. Goeddel. 1986. Tumour necrosis
factors a and b inhibit virus replication and synergize with
interferons. Nature. 323:819–822.
5. Leist, T.P., S.P. Cobbold, H. Waldmann, M. Aguet, and
R.M. Zinkernagel. 1987. Functional analysis of T lympho-
cyte subsets in antiviral host defense. J. Immunol. 138:2278–
2281.
6. Kasaian, M.T., M.K. Leite, and C.A. Biron. 1991. The role
of CD41 cells in sustaining lymphocyte proliferation during
lymphocytic choriomeningitis virus infection. J. Immunol.
146:1955–1963.
7. Leist, T.P., M. Kohler, and R.M. Zinkernagel. 1989. Im-
paired generation of antiviral cytotoxicity against lympho-
cytic choriomeningitis and vaccinia virus in mice treated with
CD4-specific monoclonal antibody. Scand. J. Immunol. 30:
679–686.
8. Matloubian, M., R.J. Conception, and R. Ahmed. 1994.
CD41 T cells are required to sustain CD81 cytotoxic T cell
responses during chronic viral infection. J. Virol. 68:8056–
8063.
9. Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and
P.C. Doherty. 1991. Clearance of influenza virus respiratory
infection in mice lacking class I major histocompatibility
complex–restricted CD81 T cells. J. Exp. Med. 174:875–880.
10. Scherle, P.A., G. Palladino, and W. Gerhard. 1992. Mice can
recover from pulmonary influenza virus infection in the ab-
sence of class I-restricted cytotoxic T cells. J. Immunol. 148:
212–217.
11. Graham, M.B., V.L. Braciale, and T.J. Braciale. 1994. Influ-
enza virus–specific CD41 T helper type 2 T lymphocytes do
not promote recovery from experimental virus infection. J.
Exp. Med. 180:1273–1282.
12. Spriggs, M.K., B.H. Koller, T. Sato, P.J. Morrissey, W.C.
Fanslow, O. Smithies, R.F. Voice, M.B. Widmer, and C.R.
Maliszewski. 1992. b2-microglobulin-, CD81 T-cell-defi-
cient mice survive inoculation with high doses of vaccinia vi-
rus and exhibit altered IgG responses. Proc. Natl. Acad. Sci.
USA. 89:6070–6074.
13. Kägi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Bürki,
R.M. Zinkernagel, and H. Hengartner. 1995. The roles of
perforin and Fas-dependent cytotoxicity in protection against
cytopathic and non-cytopathic viruses. Eur. J. Immunol. 25:
3256–3262.
14. Mahon, B.P., K. Katrak, A. Nomoto, A. Macadam, P.D. Mi-
nor, and K.H.G. Mills. 1995. Poliovirus-specific CD41 T
cell clones with both cytotoxic and helper activity mediate
protective humoral immunity against a lethal poliovirus in-
fection in transgenic mice expressing the human poliovirus
receptor. J. Exp. Med. 181:1285–1292.
15. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2
cells: different patterns of lymphokine secretion lead to differ-
ent functional properties. Annu. Rev. Immunol. 7:145–173.
16. Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional
diversity of helper T lymphocytes. Nature. 383:787–793.
17. O’Garra, A. 1998. Cytokines induce the development of func-
tionally heterogeneous T helper subsets. Immunity. 8:275–283.
18. Reiner, S.L., Z.E. Wang, F. Hatam, P. Scott, and R.M.
Locksley. 1993. Th1 and Th2 cell antigen receptors in exper-
imental leishmaniasis. Science. 259:1457–1460.
19. Else, K.J., F.D. Finkelman, C.R. Maliszewski, and R.K.
Grencis. 1994. Cytokine-mediated regulation of chronic in-
testinal helminth infection. J. Exp. Med. 179:347–351.
20. Urban, J.F., Jr., N. Noben-Trauth, D.D. Donaldson, K.B.
Madden, S.C. Morris, M. Collins, and F.D. Finkelman.
1998. IL-13, IL-4Ra and Stat6 are required for the expulsion
of the gastrointestinal nematode parasite Nippostrongylus brasil-
iensis. Immunity. 8:255–264.
21. Lefrancois, L. 1984. Protection against lethal viral infection
by neutralizing and nonneutralizing monoclonal antibodies:
distinct mechanisms of action in vivo. J. Virol. 51:208–214.
22. Thomsen, A.R., A. Nansen, C. Anderson, J. Johansen, O.
Marker, and J.P. Christensen. 1997. Cooperation of B and T
cells is required for survival of mice infected with vesicular
stomatitis virus. Int. Immunol. 9:1757–1766.
23. Maloy, K.J., C. Burkhart, G. Freer, T. Rülicke, H.P. Pircher,
D.H. Kono, A.N. Theofilopoulos, B. Ludewig, U. Hoff-
man-Rohrer, R.M. Zinkernagel, and H. Hengartner. 1999.
Qualitative and quantitative requirements for CD41 T cell-
mediated antiviral protection. J. Immunol. 162:2867–2874.
24. Oxenius, A., M.F. Bachmann, R.M. Zinkernagel, and H.
Hengartner. 1998. Virus-specific MHC class II-restricted
TCR-transgenic mice: effects on humoral and cellular im-
mune responses after viral infection. Eur. J. Immunol. 28:390–
400.
25. Mombaerts, P., E. Mizoguchi, H.G. Ljunggren, J. Iacomini,
H. Ishikawa, L. Wang, M.J. Grusby, L.H. Glimcher, H.J.
Winn, A.K. Bhan, and S. Tonegawa. 1994. Peripheral lym-
phoid development and function in TCR mutant mice. Int.
Immunol. 6:1061–1070.
26. Assenmacher, M., J. Schmitz, and A. Radbruch. 1994. Flow
cytometric determination of cytokines in activated murine T
helper lymphocytes: expression of interleukin-10 in inter-
feron-gamma and in interleukin-4-expressing cells. Eur. J.
Immunol. 24:1097–1101.
27. Charan, S., and R.M. Zinkernagel. 1986. Antibody mediated
suppression of secondary IgM response in nude mice against
vesicular stomatitis virus. J. Immunol. 136:3057–3061.
28. Bachmann, M.F., T.M. Kündig, C. Kalberer, H. Hengartner,
and R.M. Zinkernagel. 1993. Formalin inactivation of vesic-
ular stomatitis virus impairs T-cell- but not T-help-indepen-
dent B cell responses. J. Virol. 67:3917–3922.
29. Mackett, M., T. Yilma, J.K. Rose, and B. Moss. 1985. Vac-
cinia virus recombinants: expression of VSV genes and pro-
tective immunization of mice and cattle. Science. 227:433–
435.
30. Schulz, M., P. Aichele, M. Vollenweider, F.W. Bobe, F.
Cardinaux, H. Hengartner, and R.M. Zinkernagel. 1989.
MHC dependent T cell epitopes of LCMV nucleoprotein
and their protective capacity against viral disease. Eur. J. Im-
munol. 19:1657–1667.
31. Kimmig, W., and G.F. Lehmann. 1979. The immune re-
sponse of the mouse to lymphocytic choriomeningitis virus.
I. Circulating antibodies. J. Gen. Virol. 45:703–710.
32. Burkhart, C., G. Freer, R.U. Steinhoff, Y. Li, D.H. Bishop,
R.M. Zinkernagel, and H. Hengartner. 1994. Localization of
T helper cell epitopes in the vesicular stomatitis virus: the nu-
cleoprotein is responsible for serotype cross-reactive help. Vi-
ral Immunol. 7:103–111.
33. Wagner, R.R., R.M. Snyder, and S. Yamazaki. 1970. Pro-
teins of vesicular stomatitis virus: kinetics and cellular sites of
synthesis. J. Virol. 5:548–558.
34. Scott, D.W., and R.K. Gershon. 1970. Determination of to-
tal and mercaptoethanol-resistant antibody in the same serum
sample. Clin. Exp. Immunol. 6:313–317.
35. Binder, D., and T.M. Kündig. 1991. Antiviral protection by
CD81 versus CD41 T cells: CD81 T cells correlating with2169 Maloy et al.
cytotoxic activity in vitro are more efficient in antivaccinia
virus protection than CD4-dependent interleukins. J. Immu-
nol. 146:4301–4307.
36. Burkhart, C., G. Freer, R. Castro, L. Adorini, K.H.
Wiesmüller, R.M. Zinkernagel, and H. Hengartner. 1994.
Characterization of T helper epitopes of the glycoprotein of
vesicular stomatitis virus. J. Virol. 68:1573–1580.
37. Openshaw, P., E.E. Murphy, N.A. Hosken, V. Maino, K.
Davis, K. Murphy, and A. O’Garra. 1995. Heterogeneity of
intracellular cytokine synthesis at the single-cell level in po-
larized T helper 1 and T helper 2 populations. J. Exp. Med.
182:1357–1367.
38. Leist, T.P., M. Eppler, and R.M. Zinkernagel. 1989. En-
hanced virus replication and inhibition of lymphocytic chorio-
meningitis virus disease in anti-IFN gamma-treated mice. J.
Virol. 63:2813–2819.
39. Murphy, E., K. Shibuya, N. Hosken, P. Openshaw, V.
Maino, K. Davis, K. Murphy, and A. O’Garra. 1996. Re-
versibility of T helper 1 and 2 populations is lost after long-
term stimulation. J. Exp. Med. 183:901–913.
40. Bachmann, M.F., B. Odermatt, H. Hengartner, and R.M.
Zinkernagel. 1996. Induction of long-lived germinal centers
associated with persisting antigen after viral infection. J. Exp.
Med. 183:2259–2269.
41. Maloy, K.J., B. Odermatt, H. Hengartner, and R.M. Zinker-
nagel. 1998. Interferon g-producing gd T cell-dependent an-
tibody isotype switching in the absence of germinal center
formation during virus infection. Proc. Natl. Acad. Sci. USA.
95:1160–1165.
42. Kündig, T., I. Castelmur, M.F. Bachmann, D. Abraham, D.
Binder, H. Hengartner, and R.M. Zinkernagel. 1993. Fewer
protective cytotoxic T cell epitopes than T helper cell
epitopes on vesicular stomatitis virus. J. Virol. 67:3680–3683.
43. Cudmore, S., P. Cossart, G. Griffiths, and M. Way. 1995.
Actin-based motility of vaccinia virus. Nature. 378:636–638.
44. Smith, G.L. 1999. Vaccinia virus immune evasion. Immunol.
Lett. 65:55–62.
45. Springer, T.A. 1994. Traffic signals for lymphocyte recircula-
tion and leukocyte emigration: the multistep paradigm. Cell.
76:301–314.
46. Butcher, E.C., and L.J. Picker. 1996. Lymphocyte homing
and homeostasis. Science. 272:60–66.
47. O’Garra, A., L.M. McEvoy, and A. Zlotnik. 1998. T-cell sub-
sets: chemokine receptors guide the way. Curr. Biol. 8:R646–
R649.
48. Sallusto, F., A. Lanzavecchia, and C.R. Mackay. 1998.
Chemokines and chemokine receptors in T-cell priming and
Th1/Th2-mediated responses. Immunol. Today. 19:568–574.
49. Sivike, J.T., and A. Hamann. 1998. T helper 1 and T helper
2 cells respond differentially to chemokines. J. Immunol. 160:
550–554.
50. Plakhov, I.V., C. Aoki, E.G. Arlund, and C.S. Reiss. 1995.
The earliest events in VSV infection of the murine olfactory
epithelium and entry of the central nervous system. Virology.
209:257–262.
51. Christian, A.Y., M. Barna, Z. Bi, and C.S. Reiss. 1996. Host
immune response to vesicular stomatitis virus infection of
the central nervous system in C57BL/6 mice. Viral Immunol.
9:195–205.
52. Bachmann, M.F., U. Kalinke, A. Althage, G. Freer, C.
Burkhart, H. Roost, M. Aguet, H. Hengartner, and R.M.
Zinkernagel. 1997. The role of antibody concentration and
avidity in antiviral protection. Science. 276:2024–2027.
53. Coutelier, J.P., J.T.M. Van der Logt, F.W.A. Heessen, G.
Warnier, and J.V. Van Snick. 1987. IgG2a restriction of mu-
rine antibodies elicited by viral infections. J. Exp. Med. 165:
64–69.
54. Finkelman, F.D., J. Holmes, I.M. Katona, J. Urban, M.P.
Beckmann, L.S. Park, K.A. Scholley, R.L. Coffman, T.R.
Mosmann, and W.E. Paul. 1990. Lymphokine control of in
vivo immunoglobulin isotype secretion. Annu. Rev. Immunol.
8:303–333.
55. Lee, W.T., and E.S. Vitetta. 1991. The differential expression
of homing and adhesion molecules on virgin and memory T
cells in the mouse. Cell. Immunol. 132:215–222.
56. Mackay, C.R. 1993. Homing of naive, memory and effector
lymphocytes. Curr. Opin. Immunol. 5:423–427.
57. Austrup, F., D. Westweber, E. Borges, M. Löhning, R.
Bräuer, U. Herz, H. Renz, R. Hallman, A. Scheffold, A.
Radbruch, and A. Hamann. 1997. P- and E-selectin mediate
recruitment of T helper 1 but not T helper 2 cells into in-
flamed tissues. Nature. 385:81–84.
58. Asensio, V.C., and I.L. Campbell. 1997. Chemokine gene
expression in the brains of mice with lymphocytic chorio-
meningitis. J. Virol. 71:7832–7840.
59. Kündig, T.M., M.F. Bachmann, S. Oehen, U.W. Hoffmann,
J.J.L. Simard, C.P. Kalberer, H. Pircher, P.S. Ohashi, H.
Hengartner, and R.M. Zinkernagel. 1996. On the role of an-
tigen in maintaining cytotoxic T-cell memory. Proc. Natl.
Acad. Sci. USA. 93:9716–9723.
60. Bachmann, M.F., T.M. Kündig, H. Hengartner, and R.M.
Zinkernagel. 1997. Protection against immunopathological
consequences of a viral infection by activated but not resting
cytotoxic T cells: T cell memory without “memory T cells”?
Proc. Natl. Acad. Sci. USA. 94:640–645.
61. Cerwenka, A., T.M. Morgan, A.G. Harmsen, and R.W.
Dutton. 1999. Migration kinetics and final destination of
type 1 and type 2 CD8 effector cells predict protection
against pulmonary virus infection. J. Exp. Med. 189:423–434.
62. Bi, Z., P. Quandt, T. Komatsu, M. Barna, and C.S. Reiss.
1995. IL-12 promotes enhanced recovery from vesicular sto-
matitis virus infection of the central nervous system. J. Immu-
nol. 155:5684–5689.
63. Kündig, T.M., H. Hengartner, and R.M. Zinkernagel. 1993.
T cell dependent interferon gamma exerts an antiviral effect
in the central nervous system but not in peripheral solid or-
gans. J. Immunol. 150:2316–2323.
64. Jonjic, S., I. Pavic, P. Lucin, D. Rukavina, and U.H. Koszi-
nowski. 1990. Efficacious control of cytomegalovirus infec-
tion after long-term depletion of CD81 T lymphocytes. J.
Virol. 64:5457–5464.
65. Manickan, E., M. Francotte, N. Kuklin, M. Dewerchin, C.
Molitor, D. Gheysen, M. Slaoui, and B.T. Rouse. 1995.
Vaccination with recombinant vaccinia virus expressing
ICP27 induces protective immunity against herpes simplex
virus through CD41 Th1 T cells. J. Virol. 69:4711–4716.
66. Reich, A., O. Erlwein, S. Niewiesk, V. Ter Meulen, and
U.G. Liebert. 1992. CD41 T cells control measles virus in-
fection in the central nervous system. Immunology. 76:185–
191.
67. Orange, J.S., S.F. Wolf, and C.A. Biron. 1994. Effects of IL-
12 on the response and susceptibility to experimental viral in-
fections. J. Immunol. 152:1253–1264.
68. Carr, J.A., J. Rogerson, M.J. Mulqueen, N.A. Roberts, and
R.F.G. Booth. 1997. Interleukin-12 exhibits potent antiviral
activity in experimental herpesvirus infections. J. Virol. 71:2170 CD4 T Cell Subsets in Virus Infection
7799–7803.
69. Coutelier, J.P., J. Van Broeck, and S.F. Wolf. 1995. Interleu-
kin-12 gene expression after viral infection in the mouse. J.
Virol. 69:1955–1958.
70. Oxenius, A., U. Karrer, R.M. Zinkernagel, and H. Hengart-
ner. 1999. IL-12 is not required for induction of type 1 cy-
tokine responses in viral infections. J. Immunol. 162:965–973.
71. Kägi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt,
K.J. Olsen, E. Podack, R.M. Zinkernagel, and H. Hengart-
ner. 1994. Cytotoxicity mediated by T cells and natural killer
cells is greatly impaired in perforin-deficient mice. Nature.
369:31–37.
72. Oxenius, A., R.M. Zinkernagel, and H. Hengartner. 1998.
Comparison of activation versus induction of unresponsive-
ness of virus-specific CD41 and CD81 T cells upon acute
versus persistent viral infection. Immunity. 9:449–457.